$4.89
0.347.47%
Last update: Nov 6, 4:00 PM
Entrada Therapeutics Inc (TRDA) Stock Price, Quote, News & History
TRDANASDAQ
TRDA stock fell over 15% after Entrada Therapeutics announced initial Phase 1/2 ELEVATE-45-201 study results for ENTR-601-45.
You can purchase shares of Entrada Therapeutics (NASDAQ:TRDA) through any online brokerage.
Other companies in Entrada Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Entrada Therapeutics has a consensus price target of $22.75.
The stock price for Entrada Therapeutics (NASDAQ: TRDA) is $4.89 last updated November 6, 2026 at 4:00 PM EST.
There are no upcoming dividends for Entrada Therapeutics.
Entrada Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Entrada Therapeutics.
Entrada Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's...
